Patent · US Active

Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis

US11787838B2 · kind B2 · utility

0Cited by

42References

27Claims

0Family size

Assignee

Lung Therapeutics, Inc. · US

Inventors

Dale J. Christensen · Cary, US
John J. Koleng · Austin, US

Key dates

Filing date	Dec 21, 2022
Grant date	Oct 17, 2023
Priority date	—
Expiry date	Dec 21, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.